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tors have been identified to date: Myelin-AssociatedClifford J. Woolf*
Neural Plasticity Research Group Glycoprotein (MAG) (McKerracher et al., 1994), Nogo-A
(Chen et al., 2000; GrandPre´ et al., 2000; Prinjha et al.,Department of Anesthesia and Critical Care
Massachusetts General Hospital and 2000), and Oligodendrocyte-Myelin glycoprotein (OMgp)
(Wang et al., 2002a). Heterologous expression of eachHarvard Medical School
Boston, Massachusetts 02129 independently produces potent inhibition of axonal
growth in in vitro assays. Lack of MAG in MAG knockout
mice results though in minimal regeneration (Bartsch et
al., 1995). The consequences of a loss of OMgp on
Nogo-A, a reticulon protein expressed by oligodendro-
axonal growth in vivo have not yet been examined. What
cytes, contributes to the axonal growth inhibitory ac-
of Nogo-A? Based on in vitro growth assays and in vivo
tion of central myelin in growth cone collapse and
Nogo neutralizing/antagonism studies (Bregman et al.,
neurite outgrowth in vitro assays, and antibody and
1995; Liu et al., 2002), the expectation was very high that
inhibitor studies have implicated a role for Nogo in
lack of Nogo would very substantially improve axonal
regeneration in the adult CNS in vivo. Three indepen-
growth and, in this way, promote functional recovery
dent labs have now produced Nogo knockout mice
after spinal cord lesions.
with, quite unexpectedly, three different regeneration
Three papers in the present issue of Neuron describe
phenotypes.
Nogo-deficient mice (Kim et al., 2003; Simonen et al.,
2003; Zheng et al., 2003). Substantially improved regen-
Injuries to the adult mammalian central nervous system eration was found only in the young mice lacking Nogo-
(CNS) are characterized by a failure of regrowth of tran- A/B used by Strittmatter and colleagues (Kim et al.,
sected axons. The lack of regeneration is due to a combi- 2003). Tessier-Lavigne’s group studied two lines of mu-
nation of factors: death of injured neurons, reduced ca- tant mice, one lacking all three Nogo proteins, Nogo-A,
pacity of adult neurons to grow when injured, lack of -B, and -C, and one, like the mouse used by the Stritt-
the necessary trophic molecules to support growth, and matter group, lacking Nogo-A and -B. In neither mouse
the presence of an environment hostile for any growth line, however, did they detect any evidence of increased
(Schwab and Bartholdi, 1996). That the adult CNS is axonal growth (Zheng et al., 2003). Schwab’s group pro-
nonpermissive for axonal growth has been recognized duced a mouse lacking Nogo-A, which has a compensa-
since the seminal work of Cajal. Replacing this environ- tory increase in Nogo-B in oligodendrocytes. These ani-
ment with peripheral nerve grafts, Schwann cells, or mals display a statistically significant improvement in
olfactory ensheathing glia does encourage axonal axonal growth, but the numbers of axons that grow
growth (Behar et al., 2000). What is responsible then for are few, and no improvement in functional recovery is
the nonpermissive nature of the environment in the CNS reported (Simonen et al., 2003).
for axonal growth? The axonal growth cone formed after The three isoforms of Nogo, A, B, and C, arise by
the resealing of injured axons will interact with soluble alternative splicing (Nogo-A/B) and promoter usage
secreted factors, the extracellular matrix, and cells in (Nogo-C). All isoforms share a common C-terminal do-
close proximity, all of which could abort axonal growth main of 188 amino acids (Chen et al., 2000; GrandPre´
by either activating growth cone collapse signaling in the et al., 2000; Prinjha et al., 2000). A 66 amino acid subdo-
growth cone or by physically impeding axon extension. main within the common C-terminal domain is ex-
Prevention of growth may be due to expression of pressed on the surface and binds to a GPI-linked Nogo-
growth cone collapsing guidance cues normally in- 66 receptor, NgR, expressed by neurons (Fournier et al.,
volved in development, such as the semaphorins, pro- 2001). Recently, MAG and OMgp have been shown also
duction of proteoglycans at the glial scar that may act to bind with high affinity (nM) to NgR, which is a corecep-
as a “glue” adhering to the growth cone preventing its tor with the neurotrophin p75 receptor (Liu et al., 2002;
extension, and presence in central myelin of axonal Wang et al., 2002b; Wang et al., 2002a; Wong et al.,
growth inhibitory proteins. 2002). p75 has no affinity, however, for NgR ligands, it
Central myelin, produced by oligodendrocytes, is un- is the ectodomain of NgR which binds to the three li-
doubtedly a powerful suppressor of axonal growth. Ax- gands, and signal transduction is mediated by the intra-
ons of cultured neurons do not grow into explants of
cellular domain of p75 through Rho GTPases (Woolf
adult CNS tissue, although they will grow in peripheral
and Bloechlinger, 2002). The three ligands for NgR are
nerve explants containing Schwann cell-produced my-
structurally quite unrelated; what is the basis then for
elin, and neurite outgrowth is massively reduced and
the extraordinary ligand promiscuity of NgR? Do all three
growth cones collapse when neurons are grown on or
ligands bind to the same site on NgR due to a degenerate
exposed to central myelin extracts (Schwab and
recognition code on its ectodomain, or is the ligand
Thoenen, 1985). What molecules are responsible for my-
binding promiscuity due to binding of differently shapedelin’s inhibitory actions, and would neutralizing them be
ligands to multiple separate binding spots on NgR? Asufficient to promote regeneration? Three myelin inhibi-
paper in this issue of Neuron reports on the crystal
structure of the ligand binding (leucine-rich repeat) do-
main of the human Nogo receptor (He et al., 2003). The*Correspondence: cwoolf@mgh.harvard.edu
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authors propose from their structural analysis that quite derive a line of Nogo-A/B/C mutant viable mice. Collec-
different ligand architectures—Ig-like domains for MAG, tively, these mice enable the following questions to be
a curved LRR array for OMgp, and a compact globule for addressed. Does Nogo-A have a role in the postnatal
Nogo-66—all converge on a selection of distinct binding formation of highly ordered axon fiber tracts during the
hotspots on NgR. The presence of conserved aromatic time that myelination is established, is it involved in the
residues in the curved ectodomain of NgR could provide maintenance of the stability of connectivty by preventing
for a la carte binding with each ligand choosing the collateral axonal sprouting, and does it prevent central
binding site it prefers. regeneration? In all the different mutant mice, the axonal
A peptide fragment of Nogo-66 (NEP 1-40), which growth inhibitory action of extracted central myelin was
antagonizes Nogo-A binding to NgR, eliminates much reduced in in vitro assays, indicating that Nogo-A con-
of the axonal growth inhibitory action of central myelin tributes to this activity. Although the analysis must be
in vitro and promotes axonal growth after spinal cord considered preliminary, none of the Nogo mutant mice
injury (GrandPre´ et al., 2002). Nogo-A uniquely among have any detectable neurological phenotype or obvious
the three Nogo proteins has a long N-terminal extension neuroanatomical deficits. Myelin appears normal, as do
that contains a domain that also contributes to axonal axons and oligodendrocytes. This suggests that Nogo-A
outgrowth inhibition in vitro, although by an as of yet is not involved in either the development of the CNS or
undefined receptor (Chen et al., 2000). An antibody pro- in the maintenance of axonal pathways, at least in the
duced by Schwab and colleagues against purified absence of injury.
Nogo-A (NI-250, at the time), IN-1, that has a regenera- Before discussing the effects of the different Nogo
tion promoting activity in vivo (Bregman et al., 1995) gene deletions on axonal growth, it is worth considering
recognizes, among others, an epitope on the amino- exactly what changes in axonal growth may be ex-
terminal domain of Nogo-A (Chen et al., 2000). The pre- pected, and what outcome measures are appropriate
cise topology of Nogo-A remains undetermined though, to detect them. Three forms of axonal growth can occur
and it is not clear whether the growth inhibitory amino- in the adult nervous system after injury: collateral sprout-
terminal domain is exposed on the surface of oligoden- ing (a form of plasticity or growth of the axons of intact
drocytes or is intracytoplasmic. neurons typically into denervated areas), regenerative
The three papers reporting Nogo deletions use differ-
growth, growth of injured axons originating close to the
ent strategies, and each is individually compelling. The
site of injury and continuing beyond the lesion to rees-
problem is the stark divergence in regeneration pheno-
tablish disrupted synaptic connections, and finally, re-
type reported by each group.
generative sprouting, which occurs proximal to a lesionThe Strittmatter group used a mutant mouse (Nogo-
and involves growth from intact sections of injured neu-A/B mutant) derived from an embryonic stem cell clone
rons proximal to the site of the lesion and where thegenerated by Lexicon Genetics, where the Nogo gene
axons do not grow beyond the lesion. These forms maywas disrupted as a consequence of random insertion
coexist and it is not always easy to differentiate themof a gene trap vector containing a retroviral promoter,
with bulk labeling techniques. A further problem is thata strong splice acceptor, and the geo sequence. Al-
sprouting or regeneration without establishment ofthough the trapping vector was inserted into the large
working synaptic contacts is of no functional signifi-Nogo-A-specific exon (exon 3), both Nogo-A and -B
cance. How to show restoration of function? This isexpression is disrupted, presumably due to reduced
extremely difficult. Demonstration of physical contactnogo transcription or nogo-geo fusion mRNA stability.
requires ultrastructural analysis, as light microscopyNogo-C expression appears unchanged in the gene trap
cannot reveal synapses. Ideally, an electrophysiologicalline.
demonstration of transmitter release and postsynapticThe Tessier-Lavigne group generated several Nogo
responsiveness is required to justify a claim for func-mutant mice, two of which were studied for a regenera-
tional connectivity but is rarely provided. The com-tion phenotype. One (Nogo-A/B mutant) has deletion of
monest functional outcome used is the BBB open fieldan amino-terminal genomic fragment including the en-
behavioral score, a measure of restoration of locomotortire coding region of exon 1 downstream of the ATG
function. This measure has, however, some importantstart codon. Exon 1 is shared by Nogo-A and -B, and
limitations. First, it is nonlinear and subject to observerthese were disrupted, leaving Nogo-C unaffected. A sec-
bias and interpretation. Second, untreated animals withond mouse deleting the C-terminal region common to
lesions to their corticospinal tracts (in rodents, this liesall three Nogo isoforms (Nogo-A/B/C) was generated by
in the most ventral portion of the dorsal columns) showreplacing exon 4 with a floxed neomycin resistance
recovery of spontaneous hindlimb locomotion withoutgene, resulting in the absence of all Nogo isoforms.
any demonstrable regeneration, so the meaning ofThe Schwab group generated a mutant (Nogo-A)
changes is difficult to ascertain. Third, a wide range ofwhere the large Nogo-A-specific exon (exon 3) was dis-
treatment strategies targeted at Nogo, MAG, Rho, andrupted by conventional gene targeting. Although this
proteoglycans produce effects very early, much earliermutation disrupts the same exon as that by the gene
than would be expected for regenerative growth of ax-trap insertion and eliminated Nogo-A, a very substantial
ons. This may reflect short-range collateral growth orcompensatory increase in Nogo-B in oligodendrocytes
promotion of function in the autonomous central patternwas detected.
generator (CPG) that is present in the spinal cord. TheThe Nogo-A and two Nogo-A/B mutant mice were
CPG enables synchronized alternating activity in flexorviable and fertile. The Nogo-A/B/C line was embryonic
lethal, except for a single escaper, which was used to and extensor muscles to be generated below a spinal
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cord transection, producing a rhythmic walking-like pat- nature of the lesion and the degree of label of corticospi-
tern of locomotion independent of descending input nal tracts are most unlikely given the exceptional care
from the brain (Kaegi et al., 2002). The degree to which taken by this group to exclude this possibility.
the CPG operates in mice is not known, and this may What then can explain the divergent regenerative re-
confound interpretations of recovery in the BBB, which sponses found in response to the absence of Nogo-A
may not be due to axonal growth. A final consideration in these different mutant mice? Differences in genetic
is which pathway to study. In spinal cord injury, the background? Unidentified compensatory changes gen-
descending corticospinal and the ascending dorsal col- erated by chance in both of the Tessier-Lavigne mutant
umn tracts have been most extensively investigated. mice leading to suppression of axonal growth? Loss of
The choice of which axonal pathway to study to detect another growth inhibitory factor in the Strittmatter mice
regeneration includes issues such as ease of label and due to changes in genetic loci neighboring the Nogo
capacity to detect functional recovery. A further key gene consequent on the gene trap insertion? We simply
issue is whether the neurons express and continue to do not know. Truth in science is not determined either
express after injury the molecular system targeted. For by a majority vote or even by a veto. Further work is
example, in the case of Nogo, MAG, and OMgp, do required to define exactly what role Nogo-A plays, and
pyramidal cells in the motor cortex or large dorsal root this must involve elucidating the basis for the discrepan-
ganglion cells coexpress NgR and p75? If they do not, cies in the mutant mice. In the meantime, conclusions
then they might display a lack of responsiveness to about the role of Nogo-A need to be tentative, and con-
these inhibitory factors. This information is not always siderable caution is required in even considering thera-
known for all axonal pathways studied, particularly in peutic approaches for patients based on neutralizing
mice, an increasingly favored animal model of spinal or blocking the action of Nogo-A. We are undoubtedly
cord regeneration. making rapid progress in studying why the adult CNS
The profound increase in corticospinal sprouting does not regrow but need now to pause, like a growth
found above spinal cord dorsal hemilesions and the very cone contacting central myelin, before we overcome
substantial numbers of corticospinal axons that were the barriers to successful regeneration by gaining more
observed below the lesion by the Strittmatter group in insight into the actions of Nogo and other inhibitory
their Nogo-A/B mutant mice (Kim et al., 2003) appear molecules.
to indicate that Nogo-A is indeed a major contributor to
the failure of regeneration of adult CNS neurons. A criti-
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